Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis

被引:40
作者
Selvi, E
Tripodi, SA
Catenaccio, M
Lorenzini, S
Chindamo, D
Manganelli, S
Romagnoli, R
Ietta, F
Paulesu, L
Miracco, C
Cintorino, M
Marcolongo, R
机构
[1] Univ Siena, Inst Rheumatol, I-53100 Siena, Italy
[2] Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy
[3] Univ Siena, Dept Physiol, I-53100 Siena, Italy
关键词
D O I
10.1136/ard.62.5.460
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate whether, in patients with the diffuse form of systemic sclerosis (dSSc), macrophage migration inhibitory factor (MIF) production is dysregulated. Methods: 10 patients with dSSc and 10 healthy controls, matched for age and sex, were studied. MIF expression was evaluated by immunohistochemistry on formalin fixed skin biopsies of patients with dSSc and controls. MIF levels were assayed in the sera and in the supernatants of skin cultured fibroblasts by a colorimetric sandwich enzyme linked immunosorbent assay (ELISA). MIF concentrations in culture medium samples and in serum samples were compared by Student's two tailed t test for unpaired data. Results: Anti-MIF antibody immunostained the basal and mainly suprabasal keratinocytes. Small perivascular clusters of infiltrating mononuclear cells were positive; scattered spindle fibroblast-like cells were immunostained in superficial and deep dermal layers. The serum concentrations of MIF in patients with dSSc (mean (SD) 10705.6 (9311) pg/ml) were significantly higher than in controls (2157.5 (1288.6) pg/ml; p=0.011); MIF levels from dSSc fibroblast cultures (mean (SD) 1.74 (0.16) ng/2x10(5) cells) were also significantly higher than in controls (0.6 (0.2) ng/2x10(5) cells; p=0.008). Conclusion: These results suggest that MIF may be involved in the amplifying proinflammatory loop leading to scleroderma tissue remodelling.
引用
收藏
页码:460 / 464
页数:5
相关论文
共 40 条
[11]  
FEGHALI CA, 1992, J RHEUMATOL, V19, P1207
[12]  
Galindo M, 2001, ARTHRITIS RHEUM-US, V44, P1382, DOI 10.1002/1529-0131(200106)44:6<1382::AID-ART231>3.0.CO
[13]  
2-T
[14]  
KAHALEH MB, 1986, CLIN EXP RHEUMATOL, V4, P367
[15]   INCREASED INTERLEUKIN-1 RECEPTOR, TYPE-I, AT MESSENGER-RNA AND PROTEIN LEVEL IN SKIN FIBROBLASTS FROM PATIENTS WITH SYSTEMIC-SCLEROSIS [J].
KAWAGUCHI, Y ;
HARIGAI, M ;
HARA, M ;
SUZUKI, K ;
KAWAKAMI, M ;
ISHIZUKA, T ;
HIDAKA, T ;
KITANI, A ;
KAWAGOE, M ;
NAKAMURA, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1992, 184 (03) :1504-1510
[16]  
KONDO H, 1979, J RHEUMATOL, V6, P30
[17]   CUTANEOUS ANTIGEN-STIMULATING LYMPHOKINE PRODUCTION BY LYMPHOCYTES OF PATIENTS WITH PROGRESSIVE SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
KONDO, H ;
RABIN, BS ;
RODNAN, GP .
JOURNAL OF CLINICAL INVESTIGATION, 1976, 58 (06) :1388-1394
[18]  
Leech M, 1999, ARTHRITIS RHEUM, V42, P1601, DOI 10.1002/1529-0131(199908)42:8<1601::AID-ANR6>3.0.CO
[19]  
2-B
[20]  
Leech M, 1998, ARTHRITIS RHEUM-US, V41, P910, DOI 10.1002/1529-0131(199805)41:5<910::AID-ART19>3.0.CO